SH2B3 (LNK) mutations from myeloproliferative neoplasms patients have mild loss of function against wild type JAK2 and JAK2 V617F
10.1111/bjh.12327
Saved in:
Main Authors: | Koren-Michowitz, M., Gery, S., Tabayashi, T., Lin, D., Alvarez, R., Nagler, A., Koeffler, H.P. |
---|---|
Other Authors: | MEDICINE |
Format: | Article |
Published: |
2016
|
Subjects: | |
Online Access: | http://scholarbank.nus.edu.sg/handle/10635/126854 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Relationship of JAK2 (V617F) allelic burden with clinico-haematological manifestations of philadelphia-negative myeloproliferative neoplasms
by: Yow, K.S., et al.
Published: (2021) -
JAK2 mutations in Asian patients with essential thrombocythaemia
by: Wong, G.-C., et al.
Published: (2016) -
Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia
by: Hart, S., et al.
Published: (2014) -
Role of the adaptor protein LNK in normal and malignant hematopoiesis
by: Gery, S., et al.
Published: (2016) -
Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia
by: Ikezoe, T., et al.
Published: (2016)